

# RESPONSE TO REQUEST FROM ENERGY & COMMERCE COMMITTEE RE: 340B PROGRAM

### Item 1: Follow-up to question regarding origin of \$105m on the original document per below.

In 2016, Mission Health's total value of charity and unreimbursed care was nearly \$105 million and total 2016 community investments were more than \$183 million.

The \$105m represents the amount shown as unreimbursed <u>Charity Care, Medicare, and Medicaid</u> as contained in Mission's FY16 Audit & Community Benefit Report provided per the NCHA guidelines. This calculation differs slightly from the Form 990 disclosure contained on Exhibit 3.

Mission Health Community Benefit Costs	FY 2016 (Audited)
<b>Charity Care and Other Unreimbursed</b>	<u>\$104,768,315</u>
Patient Expenses	
Community Health Improvement Programs &	\$65,103,636
Services	
Grants, MOUs, and In-Kind Contributions to	\$6,330,930
Community Groups	
Medical Education & Research	\$4,924,250
Community Activities	\$2,298,838
Total	\$183,425,969

Item 2: Exhibit 3 now includes additional disclosure as to formulas.



RESPONSE TO REQUEST FROM ENERGY & COMMERCE COMMITTEE RE: 340B PROGRAM

#### MISSION HEALTH EMPLOYEES WHO WORK WITH 340B ISSUES

#### Full time 340Bstaff

- (1) Pharmacist
- (1) Information Technology Specialist

### 340B is a part of their role at Mission Health

- CEO (1)
- COO (1)
- SVP Patient Care, President Regional Member Hospitals (1)
- 340b Authorizing Officials: Hospital Presidents (2), Regional Finance Director (2), CFO (1)
- VP, Pharmacy Services (1)
- SVP & General Counsel (1)
- Associate General Counsel assigned to all 340b issues (1)
- Chief Compliance Officer (1)
- Sr. VP, Government & Community Relations Office (2)
- SVP, Community Benefit / Facilities (1)
- VP, Finance (1)
- Pharmacy Managers (6)
- Director, Supply Chain (1)
- Director, Retail Pharmacy (1)
- Community Pharmacists (7)
- Director, Cancer Center Pharmacy (1)
- Buyers (14)
- Materials Management Staff (3)
- Internal Auditors & Managers (5)
- Medication Assistance Program Staff Mission (7)
- Medication Assistance Program Staff Angel (1)
- Finance Staff (5)
- IT Staff (2)

#### 340B Vendor

• 235+ FTE's



# RESPONSE TO REQUEST FROM ENERGY & COMMERCE COMMITTEE RE: 340B PROGRAM - CHARITY CARE PORTION

#### Community Benefit and 340B Value

	Mi	ssion I	Health Communit	y Bei	nefit and 340B Saving	gs							
	Mission Health Community Benefit Activities		Estimated	ed From Form 990									
	iviission Health Community benefit Activities		FY 2017		*FY 2016		*FY 2015		*FY 2014		*FY 2013		*FY 2012
Α	Charity Care (at Cost)	\$	42,498,415	\$	29,750,529	\$	27,963,715	\$	40,139,588	\$	26,813,895	\$	21,895,452
	Unreimbursed Medicaid			\$	5,741,221	\$	(6,170,764)	\$	(10,480,943)	\$	(19,128,851)	\$	(7,868,431)
	Unreimbursed costs (other means tested government programs)			\$	5,517	\$	7,570	\$	7,187	\$	-	\$	-
	Charity Care Patients				25,352		21,710		17,462		10,131		7,882
	# Charity Care Claims				68,764		52,790		42,105		22,571		17,286
	Community Health Improvement Programs & Services			\$	17,064,874	\$	13,564,349	\$	12,046,512	\$	10,936,554	\$	8,853,316
	Health Professions Education			\$	2,820,332	\$	2,511,966	\$	2,764,242	\$	3,119,558	\$	2,708,503
	Subsidized Health Services			\$	48,384,369	\$	49,801,556	\$	46,789,957	\$	44,099,252	\$	28,000,280
	Research			\$	1,991,197	\$	1,499,907	\$	1,449,597	\$	1,783,655	\$	1,652,313
	Cash and In-kind Contributions			\$	7,418,685	\$	5,884,532	\$	4,344,779	\$	3,757,505	\$	4,048,301
В	TOTAL Mission Health Community Benefit Activities per 990			\$	113,176,724	\$	95,062,831	\$	97,060,919	\$	71,381,568	\$	59,289,734
	Unreimbursed Medicare per Audit			\$	64,323,000	\$	55,832,000	\$	44,504,000	\$	60,033,000	\$	39,339,000
	Other Estimated Community Benefits per Audit*			\$	5,926,276	\$	(2,013,831)	\$	10,833,081	\$	12,139,432	\$	14,272,266
c	TOTAL Mission Health Community Benefit Activities per AFS*			\$	183,426,000	\$	148,881,000	\$	152,398,000	\$	143,554,000	\$	112,901,000
D	Cost of Treating Bad Debt Patients	\$	37,730,278	\$	39,679,272	\$	36,983,206	\$	33,143,490	\$	36,159,388	\$	31,487,323
E	Total Uncompensated Care (Charity + Bad Debt, A+D)	\$	80,228,693	\$	69,429,801	\$	64,946,921	\$	73,283,078	\$	62,973,283	\$	53,382,775
				1									
Avg A	Average Charity Care FY13-FY17	\$	33,433,228										
Avg E	Average Uncompensated Care FY13-FY17	\$	70,172,355										

Mission Health 340B Value	Estimated FY 2017	F	Y 2016	FY 2015	FY 2014		FY 2013	FY 2012
Angel Medical Center	\$ 1,508,789	\$	616,670	\$ 577,926	\$ 677,79	\$	172,435	\$ -
Blue Ridge	\$ 230,234	\$	272,710	\$ 388,420	\$ 981,22	в \$	513,651	\$ -
Highland-Cashiers	\$ 227,505	\$	120,897	\$ 270,535	\$ 147,01	5 \$	-	\$
McDowell	\$ 2,169,798	\$	1,613,072	\$ 736,712	\$ 837,57	2 \$	814,498	\$ 96,892
Mission	\$ 26,490,110	\$	28,099,335	\$ 24,246,755	\$ 20,860,37	7 \$	13,483,493	\$ 2,735,83
Transylvania Regional	\$ 684,568	\$	523,756	\$ 467,016	\$ 240,27	В \$	385,907	\$ 286,65
TOTAL Hospital Savings	\$ 31,311,004	\$	31,246,440	\$ 26,416,829	\$ 23,597,24	5 \$	15,369,984	\$ 3,119,38
WAC Penalty (WAC Purchases at DSH Hospitals vs. GPO Pricing)	\$ (594,799)	\$	(628,674)	\$ (614,476)	\$ (441,87	2) \$	(173,735)	
Contract Pharmacy Value	\$ 7,614,686	\$	6,822,307	\$ 9,548,399	\$ 8,265,33	\$	2,818,104	\$ -
TOTAL 340B Value to Mission Health	\$ 38,330,891	\$	37,440,073	\$ 35,350,752	\$ 31,420,70	8 \$	18,014,353	\$ 3,119,38
Average 340B Value FY13-FY17	\$ 32,111,355	]						
Total Community Benefit % per 990			8.0%	7.3%	7.9	%	6.4%	6.6
Total Community Benefit % per AFS			13.0%	11.5%	12.5	%	12.8%	12.6
Total Charity Care %			2.1%	2.2%	3.3	%	2.4%	2.4
Total Uncompensated (Bad Debt + Charity) Care %			4.9%	5.0%	6.0	%	5.6%	5.9

<sup>\*</sup>The footnote related to community benefits for the audited financial statements is prepared after Mission's year end of September 30. The initial cost reports for Medicare and Medicaid are prepared in the spring following the audit and filed at that time. Because of this timing difference, as well as others, there are changes in estimates related to community benefits. These changes in estimates flow through the current year presentation of the financials. From FY 14 through the present, Mission has not restated the estimated community benefits related to the comparative year presented in the Service to the Community footnote for the Audited Financials. The methodology for disclosing community benefits for the Audited Financial Statements is based on the ANDI reported which is used by the NCHA.

Data source for 340b value is GPO less WAC savings report from wholesaler, coupled with 340b vendor reports on value of contract pharmacy operations.

2012 data was first year of 340b vendor utilization, and reflects partial year data. Correspondingly, computed averages over the period reflect FY13-FY17.



# RESPONSE TO REQUEST FROM ENERGY & COMMERCE COMMITTEE RE: 340B PROGRAM - CHARITY CARE PORTION

## Exhibit #1B: 340B Purchases

Drug Category %

Drug Category %	Drug Category	FY2016	FY2017
	Analgesics	0.44%	0.29%
	Antidepressants	0.24%	0.03%
	Antidiabetic Agents	0.67%	0.29%
Mission Hospital	Antihyperlipidemic Agents	0.14%	0.02%
	Oncology Treatment Drugs	50.30%	53.82%
	Other	48.20%	45.55%
	Grand Total	100%	100%
	Drug Category	FY2016	FY2017
	Analgesics	1.84%	1.04%
The McDowell Hospital	Antidepressants	0.65%	0.41%
	Antidiabetic Agents	4.81%	5.97%
	Antihyperlipidemic Agents	0.75%	0.51%
	Oncology Treatment Drugs	28.39%	36.28%
	Other	63.55%	55.79%
	Grand Total	100%	100%
	Drug Category	FY2016	FY2017
	Analgesics	0.43%	0.63%
	Antidepressants	1.08%	0.51%
Blood Bides Boots and Health 1991	Antidiabetic Agents	5.39%	7.36%
Blue Ridge Regional Hospital	Antihyperlipidemic Agents	0.50%	0.31%
	Oncology Treatment Drugs	6.28%	11.07%
	Other	86.31%	80.11%
	Grand Total	100%	100%
	Drug Category	FY2016	FY2017
	Analgesics	3.85%	3.65%
	Antidepressants	0.90%	0.36%
Transylvania Regional Hospital	Antidiabetic Agents	4.93%	7.76%
Transylvania Regional Hospital	Antidiabetic Agents Antihyperlipidemic Agents	4.93% 0.76%	
Transylvania Regional Hospital			0.75%
Transylvania Regional Hospital	Antihyperlipidemic Agents	0.76%	0.75% 8.30%
Transylvania Regional Hospital	Antihyperlipidemic Agents Oncology Treatment Drugs	0.76% 10.37%	0.75% 8.30% 79.19%
Transylvania Regional Hospital	Antihyperlipidemic Agents Oncology Treatment Drugs Other	0.76% 10.37% 79.20%	0.75% 8.30% 79.19% <b>100</b> %
Transylvania Regional Hospital	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics	0.76% 10.37% 79.20% <b>100%</b>	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b>
Transylvania Regional Hospital	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category	0.76% 10.37% 79.20% 100% FY2016	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b> 0.44%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics	0.76% 10.37% 79.20% 100% FY2016 1.24%	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b> 0.44% 0.23%
Transylvania Regional Hospital  Angel Medical Center	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41%	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b> 0.44% 0.23% 3.41%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53%	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b> 0.44% 0.23% 3.41% 0.19%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68%	0.75% 8.30% 79.19% <b>100%</b> <b>FY2017</b> 0.44% 0.23% 3.41% 0.19% 7.87%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs Other	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016 0.27%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017
Angel Medical Center	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016 0.27%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017 0.16% 0.12%
	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidepressants Antidepressants Antidepressants Antidepressants Antidiabetic Agents Antidiabetic Agents Antihyperlipidemic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016 0.27% 0.38%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017 0.16% 0.12% 0.84% 0.03%
Angel Medical Center	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016 0.27% 0.38% 0.80%	7.76% 0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017 0.16% 0.12% 0.84% 0.03% 0.01%
Angel Medical Center	Antihyperlipidemic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidiabetic Agents Oncology Treatment Drugs Other Grand Total Drug Category Analgesics Antidepressants Antidepressants Antidepressants Antidepressants Antidepressants Antidiabetic Agents Antidiabetic Agents Antihyperlipidemic Agents	0.76% 10.37% 79.20% 100% FY2016 1.24% 0.41% 4.53% 0.68% 13.45% 79.70% 100% FY2016 0.27% 0.38% 0.80% 0.04%	0.75% 8.30% 79.19% 100% FY2017 0.44% 0.23% 3.41% 0.19% 7.87% 87.86% 100% FY2017 0.16% 0.12% 0.84% 0.03%

Data Source: Amerisource. Information only available for the prior 28 months